Maintenance of the postabsorptive plasma glucose concentration: Insulin or insulin plus glucagon?

American Journal of Physiology - Endocrinology and Metabolism

Volumn 289, Issue 2 52-2, 2005, Pages

  Raju, Bharathi ^a   Cryer, Philip E ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Diabetes; Glucose metabolism; Hypoglycemia

Indexed keywords

GLUCAGON; GLUCAGON RECEPTOR; GLUCOSE; HORMONE ANTAGONIST; INSULIN; SOMATOSTATIN;

GENE MUTATION; GLUCAGON RELEASE; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; HORMONAL REGULATION; HORMONE SYNTHESIS; HUMAN; INSULIN RELEASE; NONHUMAN; PRIORITY JOURNAL; RABBIT; REGULATORY MECHANISM; REVIEW;

ANIMALS; BLOOD GLUCOSE; DIETARY CARBOHYDRATES; DIETARY FATS; GLUCAGON; HUMANS; HYPOGLYCEMIA; INSULIN; INTESTINAL ABSORPTION; POSTPRANDIAL PERIOD; SOMATOSTATIN;

EID: 23044517378     PISSN: 01931849     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpendo.00460.2004     Document Type: Review

References (49)

1. Boushey RP, Abadir A, Flamez D, Baggio LL, Li Y, Berger V, Marshall BA, Finegood D, Wang TC, Schuit F, and Drucker DJ. Hypoglycemia, defective islet glucagon secretion, but normal islet mass in mice with a disruption of the gastrin gene. Gastroenterology 125: 1164-1174, 2003.
2. Boyle PJ, Shah SD, and Cryer PE. Insulin, glucagon, and catecholamines in prevention of hypoglycemia during fasting. Am J Physiol Endocrinol Metab 256: E651-E661, 1989.
3. Brand CL, Jørgensen PN, Svendsen I, and Holst JJ. Evidence for a major role for glucagon in regulation of plasma glucose in conscious nondiabetic and alloxan-induced diabetic rabbits. Diabetes 45: 1076-1083, 1996.
4. Cherrington AD. Control of glucose production in vivo by insulin and glucagon. In: Handbook of Physiology. The Endocrine System. The Endocrine Pancreas and Regulation of Metabolism. Bethesda, MD: Am. Physiol. Soc., 2001, sect. 7, vol. II, chapt. 26, p. 759-785.
5. Cherrington AD, Liljenquist JE, Shulman GI, Williams PE, and Lacy WW. Importance of hypoglycemia-induced glucose production during isolated glucagon deficiency. Am J Physiol Endocrinol Metab Gastrointest Physiol 236: E263-E271, 1979.
6. Clutter WE, Bier DM, Shah SD, and Cryer PE. Epinephrine plasma metabolic clearance rates and physiologic thresholds for metabolic and hemodynamic actions in man. J Clin Invest 66: 94-101, 1980.
7. Cryer PE. Glucose counterregulation: Prevention and correction of hypoglycemia in humans. Am J Physiol Endocrinol Metab 264: E149-E155, 1993.
8. Cryer PE. The prevention and correction of hypoglycemia. In: Handbook of Physiology. The Endocrine System. The Endocrine Pancreas and Regulation of Metabolism. Bethesda, MD: Am. Physiol. Soc., 2001, sect. 7, vol. II, chapt. 35, p. 1057-1092.
9. Duttaroy A, Zimliki CL, Gautam D, Cui Y, Mears D, and Wess J. Muscarinic stimulation of pancreatic insulin and glucagon release is abolished in MS muscarinic acetylcholine receptor-deficient mice. Diabetes 53: 1714-1720, 2004.
10. Fanelli C, Pampanelli S, Epifano L, Rambotti AM, Ciofetta M, Modarelli F, Di Vincenzo A, Annibale B, Lepore M, Lalli C, Sindaco PD, Brunetti P, and Belli GB. Relative roles of insulin and hypoglycemia on induction of neuroendocrine responses to, symptoms of, and deterioration of cognitive function in hypoglycemia in male and female humans. Diabetologia 37: 797-807, 1994.
11. Flattem N, Igawa K, Shiota M, Emshwiller MG, Neal DW, and Cherrington AD. Alpha- and beta-cell responses to small changes in plasma glucose in the conscious dog. Diabetes 50: 367-375, 2001.
12. Furuta M, Yano H, Zhou A, Rouillé Y, Holst JJ, Carroll R, Ravazzola M, Orci L, Furuta H, and Steiner DF. Defective prohormone processing and altered pancreatic islet morphology in mice lacking active SPC2. Proc Natl Acad Sci USA 94: 6646-6651, 1997.
13. Gelling RW, Du XQ, Dichmann DS, Rømer J, Huang H, Cui L, Obici S, Tang B, Holst JJ, Fledelius C, Johansen PB, Rossetti L, Jelicks LA, Serup P, Nishimura E, and Charron MJ. Lower blood glucose, hyperglucagonemia, and pancreatic α-cell hyperplasia in glucagon receptor knockout mice. Proc Natl Acad Sci USA 100: 1438-1443, 2003.
14. Gerich JE, Lorenzi M, Bier DM, Schneider V, Tsalikian E, Karam JH, and Forsham PH. Prevention of human diabetic ketoacidosis by somatostatin. N Engl J Med 292: 985-989, 1975.
15. Gerich JE, Lorenzi M, Schneider V, Karam JH, Rivier J, Guillemin R, and Forsham PH. Effects of somatostatin on plasma glucose and glucagon levels in human diabetes mellitus. N Engl J Med 291: 544-547, 1974.
16. Heller SR and Cryer PE. Hypoinsulinemia is not critical to glucose recovery from hypoglycemia in humans. Am J Physiol Endocrinol Metab 261: E41-E48, 1991.
17. Kaestner KH, Katz J, Liu Y, Drucker DJ, and Schütz G. Inactivation of the winged helix transcription factor HNF3α affects glucose homeostasis and islet glucagon gene expression in vivo. Genes Dev 13: 495-504, 1999.
18. Jiang G and Zhang BB. Glucagon and regulation of glucose metabolism. Am J Physiol Endocrinol Metab 284: E671-E678, 2003.
19. Johnson DG, Goebel CU, Hruby VJ, Bregman MD, and Trivedi D. Hyperglycemia of diabetic rats decreased by a glucagon receptor antagonist. Science 215: 1115-1116, 1982.
20. Lembo G, Capaldo B, Rendina V, Iaccarino G, Napoli R, Guida R, Trimarco B, and Sacca L. Acute noradrenergic activation induces insulin resistance in human skeletal muscle. Am J Physiol Endocrinol Metab 266: E242-E247, 1994.
21. Liang Y, Osborne MC, Monia BP, Bhanot S, Gaarde WA, Reed C, She P, Jetton TL, and Demarest KT. Reduction in glucagon receptor expression by an antisense oligonucleotide ameliorates diabetic syndrome in db/db mice. Diabetes 53: 410-417, 2004.
22. Liljenquist JE, Mueller GL, Cherrington AD, Keller U, Chiasson JL, Perry JM, Lacy WW, and Rabinowitz D. Evidence for an important role of glucagon in the regulation of hepatic glucose production in normal man. J Clin Invest 59: 369-374, 1977.
23. Lins PE and Efendic S. Hyperglycemia induced by somatostatin in normal subjects. Horm Metab Res 8: 497-498, 1976.
24. Lins PE, Wajngot A, Adamson U, Vranic M, and Efendic S. Minimal increases in glucagon levels enhance glucose production in man with partial hypoinsulinemia. Diabetes 32: 633-636, 1983.
25. + channels in the hypothalamus are essential for maintenance of glucose homeostasis. Nature Neuroscience 4: 507-512, 2001.
26. Miki T, Nagashima K, Tashiro F, Kotake K, Yoshitomi H, Tamamoto A, Gonoi T, Iwanaga T, Miyazaki JI, and Seino S. Defective insulin secretion and enhanced insulin action in KATP channel-deficient mice. Proc Natl Acad Sci USA 95: 10402-10406, 1998.
27. Mitrakou A, Kelley D, Veneman T, Jenssen T, Pangburn T, Reilly J, and Gerich J. Contribution of abnormal muscle and liver glucose metabolism to postprandial hyperglycemia in NIDDM. Diabetes 39: 1381-1390, 1990.
28. Mitrakou A, Ryan C, Veneman T, Mokan M, Jensen T, Kiss I, Durant J, Cryer P, and Gerich J. Hierarchy of glycemic thresholds for counter-regulatory hormone secretion, symptoms and cerebral dysfunction. Am J Physiol Endocrinol Metab 260: E67-E74, 1991.
29. Müller WA, Faloona GR, Aguilar-Parada E, and Unger RH. Abnormal alpha cell function in diabetes: Response to carbohydrate and protein ingestion. N Engl J Med 283: 109-115, 1970.
30. Myers SR, Diamond MP, Adkins-Marshall BA, Williams PE, Stinsen R, and Cherrington AD. Effects of small changes in glucagon on glucose production during a euglycemic, hyperinsulinemic clamp. Metabolism 40: 66-71, 1991.
31. Navegantes LCC, Sjöstrand M, Gudbjörnsdottir S, Strindbergh EM, and Lönnroth P. Regulation and counterregulation of lipolysis in vivo: Different roles of sympathetic activation and insulin. J Clin Endocrinol Metab 88: 5515-5520, 2003.
32. Parker JC, Andrews KM, Allen MR, Stock JL, and McNeish JD. Glycemic control in mice with targeted disruption of the glucagon receptor gene. Biochem Biophys Res Commun 290: 839-843, 2002.
33. Parker JC, McPherson RI, Andrews KM, Levy CB, Dubins JS, Chin JE, Perry PV, Hulin B, Perry DA, Inagaki T, Dekker KA, Tachikawa K, Sugie Y, and Treadway JL. Effects of skyrin, a receptor-selective glucagon antagonist, in rat and human hepatocytes. Diabetes 49: 2079-2086, 2000.
34. Paty BW, Ryan EA, Shapiro AMJ, Lakey JRT, and Robertson RP. Intrahepatic islet transplantation in type 1 diabetic patients does not restore hypoglycemic hormonal counterregulation or symptom recognition after insulin independence. Diabetes 51: 3428-3434, 2002.
35. Petersen KF and Sullivan JT. Effects of a novel glucagon receptor antagonist (Bay 27-9955) on glucagon-stimulated glucose production in humans. Diabetologia 44: 2018-2024, 2001.
36. Raju B and Cryer PE. Mechanism, temporal relationships and magnitudes of the metabolic responses to the KATP channel agonist diazoxide. Am J Physiol Endocrinol Metab 288: E80-E85, 2005.
37. Raskin P, Aydin I, Yamamoto T, and Unger RH. Abnormal alpha cell function in human diabetes. Am J Med 64: 988-997, 1978.
38. Reaven GM, Chen YD, Golay A, Swislocki AL, and Jaspan JB. Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 64: 106-110, 1987.
39. Roden M, Stingl H, Chandramouli V, Schumann WG, Hofer A, Landau BR, Nowotny P, Waldhäusl W, and Shulman GI. Effects of free fatty acid elevation on postabsorptive endogenous glucose production and gluconeogenesis in humans. Diabetes 49: 701-707, 2000.
40. Rosen SG, Clutter WE, Berk MA, Shah SD, and Cryer PE. Epinephrine supports the postabsorptive plasma glucose concentration and prevents hypoglycemia when glucagon secretion is deficient in man. J Clin Invest 73: 405-411, 1984.
41. Rosen SG, Clutter WE, Shah SD, Miller JP, Bier DM, and Cryer PE. Direct α-adrenergic stimulation of hepatic glucose production in human subjects. Am J Physiol Endocrinol Metab 245: E616-E626, 1983.
42. Ryan EA, Shandro T, Green K, Paty BW, Senior PA, Bigam D, Shapiro AMJ, and Vantyghem MC. Assessment of the severity of hypoglycemia and glycemic lability in type 1 diabetic subjects undergoing islet transplantation. Diabetes 53: 955-962, 2004.
43. Schwartz NS, Clutter WE, Shah SD, and Cryer PE. Glycemic thresholds for activation of glucose counterregulatory systems are higher than the threshold for symptoms, J Clin Invest 79: 777-781, 1987.
44. Sherwin RS, Hendler R, DeFronzo R, Wahren J, and Felig P. Glucose homeostasis during prolonged suppression of glucagon and insulin secretion by somatostatin. Proc Natl Acad Sci USA 74: 348-352, 1977.
45. Sloop KW, Cao JXC, Siesky AM, Zhang HY, Bodenmiller DM, Cox AL, Jacobs SJ, Moyers JS, Owens RA, Showalter AD, Brenner MB, Raap A, Gromada J, Berridge BR, Monteith DKB, Porksen N, McKay RA, Monia BP, Bhanot S, Watts LM, and Michael MD. Hepatic and glucagon-like peptide-1 mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors. J Clin Invest 113: 1571-1581, 2004.
46. Soybel D, Jaspan J, Polonsky K, Goldberg I, Rayfield E, and Tager H. Differential immunoreactivity of plasma glucagon components in man: studies with different antibodies. J Clin Endocrinol Metab 56: 612-618, 1983.
47. Staehr P, Hother-Nielsen O, Landau BR, Chandramouli V, Holst JJ, and Beck-Nielsen H. Effects of free fatty acids per se on glucose production, gluconeogenesis, and glycogenolysis. Diabetes 52: 260-267, 2003.
48. Unger RH and Orci L. The essential role of glucagon in the pathogenesis of diabetes mellitus. Lancet 1: 14-16, 1975.
49. Webb GC, Akbar MS, Zhao C, Swift HH, and Steiner DF. Glucagon replacement via micro-osmotic pump corrects hypoglycemia and α-cell hyperplasia in prohormone convertase 2 knockout mice. Diabetes 51: 398-405, 2002.